What changed for Parkinson's Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Parkinson's Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 20 to 19 (-1)
- Trials recruiting worldwide 530 to 540 (+10)
- Trials on record 3,685 to 3,752 (+67)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Parkinson's Disease in July 2026. Voxsanity tracks 14 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 145 trials tracked for Parkinson's Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT01883505 · results posted 9 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT01883505) looked at what happens at the skin site when a medication called ND0612 is delivered under the skin through a small pump. In the first part of the trial (a 14-day blinded phase, meaning neither participants nor researchers knew who received which treatment), 19 people received ND0612 and 11 received a placebo (an inactive dummy treatment). A smaller, optional second phase ran for 7 days and involved 16 people split across two ND0612 groups. All participants who started each phase completed it, with no drop-outs r...
-
NCT03516981 · results posted 8 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03516981) enrolled 245 participants across four treatment groups: 81 people received pembrolizumab combined with lenvatinib, 83 received pembrolizumab combined with quavonlimab, 30 received pembrolizumab combined with favezelimab at a lower dose (200 mg), and 51 received pembrolizumab combined with favezelimab at a higher dose (800 mg). The trial was measuring how these different drug combinations performed in people with cancer, using tumour biology markers to divide participants into subgroups. The main thing being measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04759898 · results posted 1 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people with Parkinson's disease who were already undergoing deep brain stimulation surgery. All 20 participants completed the study, and none dropped out. The trial was measuring whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS — where a very mild electrical current is applied to the scalp) was associated with any change in a particular type of brain signal activity in the part of the brain that controls movement. Specifically, it looked at what are called "bet...
-
NCT03867084 · results posted 24 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03867084) enrolled 476 people in the pembrolizumab group and 483 people in the placebo group — a total of 959 participants. The trial was studying pembrolizumab (an immunotherapy medicine) compared to a placebo (an inactive treatment) in people with hepatocellular carcinoma (a type of liver cancer). The trial tracked a number of secondary outcomes, including how many people experienced unwanted health events (called adverse events), and changes in participants' quality of life and physical wellbeing using standardised ques...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05116189 · results posted 9 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05116189) enrolled 643 people in total — 322 in the group receiving pembrolizumab combined with paclitaxel (with or without bevacizumab), and 321 in the group receiving a placebo combined with paclitaxel (with or without bevacizumab). The trial was measuring how long participants went without their disease getting worse — a timeframe researchers call "progression-free survival" — comparing the two groups. This was looked at both across all participants and within a smaller subgroup whose tumours had a particular biological...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06263673 · results posted 28 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06263673) enrolled 13 people with Parkinson's disease across three groups — four participants took sitagliptin (a diabetes medication), four took dapagliflozin (another diabetes medication), and five took a placebo (a dummy treatment with no active ingredient). One person in the placebo group did not complete the study. The trial was measuring changes in Parkinson's disease symptom scores and a basic memory and thinking test over the course of the study. The reported data shows changes in the MDS-UPDRS — a scale where hig...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04617496 · results posted 7 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04617496) involved 104 participants in total — 50 in the group that received a combined speech and exercise intervention, and 54 in a control group. By the end of the study, 45 participants in the intervention group and 50 in the control group had completed it. The trial was measuring changes in two things over six months: how clearly participants could be understood when speaking (called "speech intelligibility"), and how well participants felt they could communicate in everyday situations. The reported data shows that f...
-
NCT04221945 · results posted 5 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04221945) enrolled 1,060 people in total — 529 in the group receiving chemoradiotherapy (chemotherapy combined with radiation) plus pembrolizumab (an immunotherapy medicine), and 531 in the group receiving chemoradiotherapy plus a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring two things: how long people went without their cancer growing or spreading (called progression-free survival), and how long people survived overall (overall survival). The reported data shows that for progre...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05905302 · results posted 23 December 2025
According to the results reported on ClinicalTrials.gov, this trial involved 15 people in total — 8 in one group and 7 in another. It used a "crossover" design, meaning each person tried both types of exercise: voluntary exercise (where participants pedalled a stationary bike at their own pace) and forced exercise (where the bike was motorised to pedal at a faster rate). All 15 participants completed every stage of the trial. The study was measuring how the two types of exercise affected motor (movement) function and brain activity patterns in people with Parkinson's disease who had a deep bra...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04704219 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04704219) enrolled 160 people, all of whom received a combination of two medicines: pembrolizumab and lenvatinib. Of those, 158 actually received treatment. The trial was measuring how tumours responded to this combination, as well as tracking how long any response lasted, how long participants lived without their disease getting worse, and how long they lived overall. No participants were recorded as having formally "completed" the study, which the reported data indicates reflects how the trial was structured rather than...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04662710 · results posted 28 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04662710) involved two parts. A small safety check (Part 1) enrolled 15 people who received a combination of lenvatinib, pembrolizumab, and chemotherapy. The larger main study (Part 2) enrolled 880 people — 443 received the three-drug combination and 437 received chemotherapy alone. The trial was measuring, among other things, how long people lived overall, how long it was before their disease progressed or worsened, and what kinds of unwanted medical events (called adverse events) occurred. The reported data shows that i...
-
NCT04223193 · results posted 21 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04223193) enrolled 304 people with Parkinson's disease — 153 received a placebo (a dummy treatment) and 151 received a medicine called tavapadon. Of those who started, 130 in the placebo group and 94 in the tavapadon group completed the study. The trial's main goal was to measure changes in a standard Parkinson's rating scale called the MDS-UPDRS, which scores movement and day-to-day motor difficulties on a range from 0 (normal) to 184 (most severe) for the sections combined. A lower (more negative) change from the startin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05064059 · results posted 17 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05064059) enrolled 441 people with advanced colorectal cancer — 221 in the group receiving a combination of two immunotherapy medicines called favezelimab and pembrolizumab, and 220 in a group receiving one of two standard chemotherapy medicines (regorafenib or TAS-102). The trial was primarily measuring how long participants lived overall, and secondarily looking at how long the cancer took to worsen, how many participants' tumours shrank, how long those responses lasted, and how many participants experienced unwanted med...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03740165 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03740165) enrolled 1,367 people across three treatment groups. Participants were randomly assigned to one of three chemotherapy combinations: carboplatin and paclitaxel alone (454 people), carboplatin and paclitaxel plus pembrolizumab (458 people), or carboplatin and paclitaxel plus both pembrolizumab and olaparib (455 people). The trial was primarily measuring "progression-free survival" — that is, how long participants went without their disease visibly worsening or without dying. This was tracked both across all partici...
-
NCT04746846 · results posted 22 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04746846) involved 12 participants who all completed the study. There was only one group: people who received vibration therapy. The trial was measuring "freezing of gait" — a symptom of Parkinson's disease where a person suddenly feels unable to move their feet while walking. Researchers counted how many of these freezing episodes occurred and how long each one lasted, comparing results when participants were and were not receiving vibration. The reported data shows that the number of freezing episodes across the differe...
-
NCT03765918 · results posted 20 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03765918) enrolled 363 people in the pembrolizumab-plus-standard-care group and 351 people in the standard-care-only group — a total of 714 participants. The trial was looking at treatments for a type of head and neck cancer, and was measuring how well tumours responded to treatment before surgery. Specifically, it tracked two things after surgeons removed the tumour: whether very little cancer remained (called a "major pathological response," or mPR — meaning 10% or less of the removed tissue still contained active cancer...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04201093 · results posted 28 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04201093) enrolled 529 people with Parkinson's disease across three groups: 175 received a placebo (dummy treatment), 177 received a 5 mg dose of tavapadon, and 177 received a 15 mg dose of tavapadon. The trial's main goal was to measure changes in a widely used Parkinson's rating scale called the MDS-UPDRS, which scores motor symptoms and how they affect daily life — a lower (more negative) change from the starting score indicates improvement, while a higher (more positive) change indicates worsening. By the end of the st...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04799418 · results posted 3 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04799418) involved people living with Parkinson's disease and was an open-label extension study — meaning all participants received the active treatment after a previous randomised controlled trial where some had received a passive (inactive) version. A total of 148 people started the study (69 in the "passive-then-active" group and 79 in the "active-then-active" group), and 96 completed it. The trial was primarily measuring changes in non-motor symptoms of Parkinson's disease — things like sleep problems, mood, and other...
-
NCT05421624 · results posted 31 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05421624) enrolled 44 people with Parkinson's disease — 22 in a group called "Amped-PD" and 22 in an "Active-Control" group. Most participants finished the trial: 21 in the Amped-PD group and 20 in the Active-Control group. The trial was measuring two main things: how many minutes per day participants spent walking at a moderate pace (defined as taking more than 100 steps per minute), and how many total steps they took each day. Both were tracked using a research-grade activity monitor worn on the leg. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05753449 · results posted 28 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05753449) looked at two different settings for deep brain stimulation (DBS) — a device implanted in the brain used for Parkinson's disease — in a very small group of participants. Specifically, the trial compared a standard DBS setting against an experimental "burst-type" setting, where the device delivers stimulation in short pulses rather than continuously. The main thing being measured was motor (movement) symptoms using a standard Parkinson's rating tool called the UPDRS-III, where scores range from 0 (no problems) to...
-
NCT04428151 · results posted 25 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04428151) enrolled 374 people in total across three groups: 144 people received a combination of lenvatinib and pembrolizumab, 142 people received standard-of-care (SOC) chemotherapy, and 88 people received lenvatinib on its own. The trial was measuring how these treatments compared on several outcomes, including how long people lived overall, how long it took for their cancer to worsen or for them to die, how many people's tumours shrank, and how long those responses lasted. No participants were recorded as having formall...
-
NCT03179436 · results posted 8 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03179436) enrolled a total of 415 participants across 12 different treatment groups. The trial was testing various doses and dosing schedules of an investigational drug called MK-1308 (also given in some groups as a combined formulation called MK-1308A), either alone or together with a second drug called pembrolizumab. The trial was designed to look at how participants responded to different doses and combinations, how the drugs moved through the body, and to track any unwanted medical events (called adverse events) that o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04542499 · results posted 25 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04542499) enrolled 507 people with Parkinson's disease — 255 in the placebo group and 252 in the tavapadon group. The trial was measuring changes in how participants spent their time across the day, specifically how many hours they experienced what is called "on" time (periods when their Parkinson's symptoms were better controlled) without troublesome involuntary movements, and how many hours they spent in "off" time (periods when symptoms were poorly controlled). Participants tracked this themselves using a diary tool cal...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04292223 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04292223) enrolled 29 adults who were given pimavanserin 34 mg. The trial was a single-group study — meaning everyone received the same treatment, with no comparison group — and it ran for 16 weeks. The main thing being measured was how participants' day-to-day functioning changed over that time, using a questionnaire called the modified Functional Status Questionnaire (mFSQ), which scores overall functional ability on a scale from 0 to 100, where higher numbers mean better functioning. Several secondary measures were also...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05586490 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05586490) looked at a research device being tested with people living with Parkinson's disease. The study was broken into three separate aims. Aim 1 involved 18 participants and focused on how easy and acceptable the device was to use in a lab setting. Aim 2 involved 8 participants (4 who had started in Aim 1 and 4 new participants) and looked at whether certain physical performance tests showed any change before and after using the device. Aim 3 tested the device in people's homes across three groups — one using the resea...
-
NCT03833427 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03833427) tested a combination of two medicines — selumetinib and pembrolizumab — in 32 participants in total. Participants were divided into groups receiving different doses of selumetinib (50 mg, 75 mg, 100 mg, and 125 mg), each combined with pembrolizumab. The higher dose groups (150 mg, 200 mg, and above 200 mg) had no participants enrolled. The trial was primarily looking at whether the combination caused certain serious side effects — called dose-limiting toxicities — and tracking any unwanted health events (called a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05008224 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05008224) enrolled 146 people with a form of lymphoma (a cancer of the lymph system). All 146 received at least one dose of pembrolizumab (an immunotherapy drug), 136 went on to receive a chemotherapy combination called AVD, and 17 received a different, more intensive chemotherapy called escBEACOPP. The trial was measuring how many participants achieved what is called a "complete response" — meaning scans showed no detectable signs of disease — after finishing the full treatment course. It also tracked how scan results cha...
-
NCT03374254 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03374254) enrolled a total of 116 people across nine treatment groups, testing different combinations of cancer medicines — pembrolizumab, binimetinib, and chemotherapy regimens known as mFOLFOX7 and FOLFIRI — in people with advanced colorectal cancer. The trial was split into parts, and none of the participants were recorded as having "completed" the study in the formal sense, meaning all participants exited the study early for various reasons (which is common in trials of this type). The reported data shows that the mai...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03776136 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03776136) enrolled 103 adults who all received a combination of two medicines — lenvatinib and pembrolizumab. All 103 participants were treated, and none were recorded as having "completed" the study, meaning the trial ended or participants left before a formal completion point was reached. The trial was primarily measuring how many participants' tumours shrank or disappeared (called the "objective response rate"), and it also tracked how long before the disease got worse, how long participants survived overall, and how lo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03976375 · results posted 22 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03976375) enrolled 422 people across three groups: 185 received a combination of pembrolizumab and lenvatinib, 189 received docetaxel, and 48 received lenvatinib on its own. The trial was measuring how long participants lived overall (called overall survival), how long they lived before their cancer grew or spread further (called progression-free survival), how many participants' tumours shrank or disappeared (called objective response rate), and how long those responses lasted. The reported data shows that for overall su...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 145 reported results for Parkinson's Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, Parkinson's Disease currently attracts a very large amount of public research investment from the United States government, and that level of investment has remained broadly steady over recent years. For patients, this signals that Parkinson's Disease is firmly established as a serious research priority, with sustained scientific attention being directed toward under...
See the full Parkinson's Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.